Organogenesis Holdings Inc. Files 8-K

TL;DR

ORG filed an 8-K on 9/25/25 covering Reg FD, other events, and financials.

AI Summary

Organogenesis Holdings Inc. filed an 8-K on September 25, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is based in Canton, MA, and operates in the Pharmaceutical Preparations sector.

Why It Matters

This 8-K filing provides updates on regulatory disclosures and other corporate events for Organogenesis Holdings Inc., which could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting various corporate events and disclosures, not indicating any immediate material adverse changes.

Key Numbers

• 001-37906 — SEC File Number (Identifies the company's filing with the SEC.)
• 98-1329150 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Organogenesis Holdings Inc. (company) — Registrant
• September 25, 2025 (date) — Date of Report
• Canton, MA (location) — Principal executive offices
• Avista Healthcare Public Acquisition Corp. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.0001 — which registered Class A Common Stock, $0.0001 par value ORGO Nasdaq Capital Marke

Filing Documents

• d870311d8k.htm (8-K) — 32KB
• d870311dex991.htm (EX-99.1) — 15KB
• d870311dex992.htm (EX-99.2) — 63KB
• g870311g0926003036049.jpg (GRAPHIC) — 2KB
• 0001193125-25-217810.txt ( ) — 237KB
• orgo-20250925.xsd (EX-101.SCH) — 3KB
• orgo-20250925_lab.xml (EX-101.LAB) — 17KB
• orgo-20250925_pre.xml (EX-101.PRE) — 11KB
• d870311d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as "intend," "seek," "anticipate," "believe," "expect," "estimate," "potential" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements concern, and these risks and uncertainties include, among others: the risks and uncertainties inherent in clinical development; the FDA may require additional evidence for ReNu before we can submit a BLA or get a BLA approved, which we may not be able to obtain; that other clinical trials of ReNu may produce different results; the likelihood and timing of possible regulatory approval and commercial launch of ReNu; determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to develop or commercialize ReNu; ongoing regulatory obligations and oversight impacting ReNu; unforeseen safety issues resulting from the administration of ReNu in patients; competing products and product candidates that may be superior to our products and product candidates; uncertainty of market acceptance and commercial success of ReNu and the impact of studies (whether conducted by us or others and whether mandated or voluntary) on the commercial success of ReNu; our ability to manufacture and manage supply components for ReNu; the availability and extent of reimbursement of ReNu from third-party payers, including private payer healthcare and insurance programs and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers, including local coverage determinations by Medicare Part A/B Medicare Administrative Contractors; new policies and procedures

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 25, 2025 99.2 Data from Phase 3 RCTs of ReNu dated September 25, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Organogenesis Holdings Inc. By: /s/ Lori Freedman Name: Lori Freedman Title: Chief Administrative and Legal Officer Date: September 25, 2025

View Full Filing

View this 8-K filing on SEC EDGAR